- Home
- ONCY
as 12-18-2024 10:41am EST
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
| Founded: | 1998 | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 86.1M | IPO Year: | 1999 |
| Target Price: | $4.00 | AVG Volume (30 days): | 359.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.27 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.76 - $1.53 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oncolytics Biotech Inc. News
ONCY Breaking Stock News: Dive into ONCY Ticker-Specific Updates for Smart Investing
MT Newswires
2 hours ago
Oncolytics Biotech to Present "Promising" Pelareorep Data at ASCO GI Symposium
PR Newswire
4 hours ago
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium
MT Newswires
15 days ago
Oncolytics Biotech Competes Safety Phase Enrollment for GOBLET Trial's Pancreatic Cancer Cohort
CNW Group
15 days ago
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort
GuruFocus.com
a month ago
Oncolytics Biotech Inc (ONCY) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
MT Newswires
a month ago
Oncolytics Biotech Q3 Loss Narrows
PR Newswire
a month ago
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
PR Newswire
a month ago
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
Compare ONCY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ONCY Oncolytics Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.